Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyCellularComponentZ disc

RYR2 SLC4A1 NEB

4.47e-04151213GO:0030018
GeneOntologyCellularComponentI band

RYR2 SLC4A1 NEB

5.89e-04166213GO:0031674
MousePhenopostnatal lethality, complete penetrance

SLC18A2 EIF2AK3 RYR2 SLC4A1 NEB

1.04e-04445165MP:0011085
MousePhenolethality during fetal growth through weaning, incomplete penetrance

SLC18A2 EIF2AK3 RYR2 SLC4A1 GCM2 PRDM1 NEB

1.28e-041124167MP:0011112
MousePhenolethality, incomplete penetrance

ITSN1 RYR2 SLC4A1 GCM2

1.73e-04258164MP:0010831
MousePhenoenlarged mesenteric lymph nodes

LIPA RYR2

2.08e-0419162MP:0008466
MousePhenoabnormal third pharyngeal arch morphology

GCM2 PRDM1

2.08e-0419162MP:0006339
MousePhenoincreased urine calcium level

SLC4A1 GCM2

2.80e-0422162MP:0005441
MousePhenopostnatal growth retardation

SLC18A2 EIF2AK3 RC3H1 ITSN1 SLC4A1 NEB

2.85e-04881166MP:0001732
MousePhenoabnormal postnatal growth

SLC18A2 EIF2AK3 RC3H1 ITSN1 SLC4A1 NEB

3.34e-04907166MP:0001731
MousePhenoabnormal renal filtration rate

SLC14A1 SLC4A1

4.56e-0428162MP:0005556
DomainSH3_9

ARHGEF38 ITSN1 NEB

1.02e-0478223PF14604
DomainSH3

ARHGEF38 ITSN1 NEB

2.00e-03216223PS50002
DomainSH3

ARHGEF38 ITSN1 NEB

2.00e-03216223SM00326
DomainSH3_domain

ARHGEF38 ITSN1 NEB

2.10e-03220223IPR001452
DomainDH_1

ARHGEF38 ITSN1

2.48e-0363222PS00741
DomainRhoGEF

ARHGEF38 ITSN1

2.88e-0368222SM00325
DomainDH_2

ARHGEF38 ITSN1

3.05e-0370222PS50010
DomainRhoGEF

ARHGEF38 ITSN1

3.05e-0370222PF00621
DomainDH-domain

ARHGEF38 ITSN1

3.13e-0371222IPR000219
Domain-

ARHGEF38 ITSN1

3.13e-03712221.20.900.10
DomainSH3_2

ARHGEF38 ITSN1

4.56e-0386222IPR011511
DomainSH3_2

ARHGEF38 ITSN1

4.56e-0386222PF07653
DomainC2

MYOF ITSN1

1.03e-02131222PF00168
Pubmed

A knock-in mouse model of N-terminal R420W mutation of cardiac ryanodine receptor exhibits arrhythmogenesis with abnormal calcium dynamics in cardiomyocytes.

RC3H1 RYR2

3.82e-07222225193700
Pubmed

HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization.

EIF2AK3 RYR2

5.72e-06622219009018
Pubmed

ER stress disrupts Ca2+-signaling complexes and Ca2+ regulation in secretory and muscle cells from PERK-knockout mice.

EIF2AK3 RYR2

5.72e-06622216352659
Pubmed

Follow-up examination of linkage and association to chromosome 1q43 in multiple sclerosis.

RYR2 ECE2

7.21e-052022219626040
Pubmed

L-type voltage-dependent calcium channel alpha subunit 1C is a novel candidate gene associated with secondary hyperparathyroidism: an application of haplotype-based analysis for multiple linked single nucleotide polymorphisms.

SLC14A1 RYR2 SLC4A1

9.90e-0514322320424473
Pubmed

Blood pressure is regulated by an alpha1D-adrenergic receptor/dystrophin signalosome.

RYR2 NEB

1.33e-042722218468998
Pubmed

Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications.

ITSN1 NEB

1.43e-042822218067320
Pubmed

A novel view of the transcriptome revealed from gene trapping in mouse embryonic stem cells.

EIF2AK3 ITSN1

2.94e-044022217540781
Pubmed

A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication.

SLC18A2 SLC4A1 PRDM1

3.43e-0421822319460752
Pubmed

The Interleukin-2-mTORc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells.

EIF2AK3 ITSN1 PRDM1

3.86e-0422722326410627
Pubmed

Yin Yang 1 sustains biosynthetic demands during brain development in a stage-specific manner.

UTP20 NDUFA3

4.06e-044722231097699
CytobandEnsembl 112 genes in cytogenetic band chr1q25

RC3H1 SMG7

2.90e-03167222chr1q25
CytobandEnsembl 112 genes in cytogenetic band chr10q23

MYOF LIPA

3.92e-03195222chr10q23
GeneFamilyGlycosyltransferase family 6|Blood group antigens

SLC14A1 SLC4A1

3.65e-0437142454
GeneFamilyPleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing

ARHGEF38 ITSN1

1.16e-0366142722
GeneFamilySolute carriers

SLC14A1 SLC18A2 SLC4A1

3.15e-03395143752
GeneFamilyEF-hand domain containing

ITSN1 RYR2

1.21e-02219142863
ToppCell(2)_unknow|World / Spleen cell shreds - cell class (v1) and cell subclass (v1)

SLC14A1 ITSN1 SLC4A1

2.81e-051212230090aef3d8a42968828edc637773ef99b2940dde
ToppCell(2)_Unknown|World / Spleen cell shreds - cell class (v1) and cell subclass (v1)

SLC14A1 ITSN1 SLC4A1

2.81e-051212236689c9016f29ce6a16824614b6229a71c42babb5
ToppCellMegakaryocytic-erythropoietic-Erythro-cells-Erythrocyte|Erythro-cells / Lineage, cell class and subclass

SLC14A1 ITSN1 SLC4A1

4.73e-051442237fbedc65314cfb06bcc527d794b5de7858f7c5ec
ToppCellfacs-Trachea-nan-18m-Myeloid-lymphocyte_of_B_lineage|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC14A1 ZNF585A PRDM1

6.47e-051602235c9281706009558c8361bfa76169f43ffc0f7947
ToppCelldroplet-Fat-SCAT-30m-Hematologic-nan|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC18A2 SLC4A1 NEB

6.47e-0516022367ee7a314d7d4d3ea206e0158083f36f6dd7e80b
ToppCelldroplet-Fat-SCAT-30m-Hematologic-erythroblast|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC18A2 SLC4A1 NEB

6.47e-05160223fc76337ad766c859db390ef8b6fb9caeaace3a56
ToppCelldroplet-Fat-SCAT-30m-Hematologic|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC18A2 SLC4A1 NEB

6.47e-05160223759749f708c3a2b36692d42499f19aff937e592f
ToppCellfacs-Trachea-18m-Hematologic-lymphocytic-B_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

SLC14A1 ZNF585A PRDM1

6.96e-051642234274a4f225cabf61f0fe27d8ea162b4eba612f87
ToppCellfacs-Trachea-18m-Hematologic-lymphocytic-B_cell-B_cell_of_the_trachea|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

SLC14A1 ZNF585A PRDM1

6.96e-05164223d62143450f59097ad4b34603a6257f897a769ead
ToppCell11.5-Airway-RBC-RBC|Airway / Age, Tissue, Lineage and Cell class

SLC14A1 SLC18A2 SLC4A1

7.09e-051652238618b2c5659aa70c7c9d6e51a227ac612b4ad17b
ToppCell11.5-Airway-RBC|Airway / Age, Tissue, Lineage and Cell class

SLC14A1 SLC18A2 SLC4A1

7.09e-0516522346042340a373adaf1c439b2301e02fbae3e31a4f
ToppCellCOVID-19-lung-RBC|lung / Disease (COVID-19 only), tissue and cell type

SLC14A1 SLC18A2 SLC4A1

7.88e-051712230e8d63c8fbccdda4f1ef00de00667a50464b104b
ToppCellCOVID-19-lung-RBC|COVID-19 / Disease (COVID-19 only), tissue and cell type

SLC14A1 SLC18A2 SLC4A1

8.44e-051752234c35292ad2ac712ba7516f27dd6eac6ba8fdd163
ToppCellPCW_13-14-Hematologic_ErythroMegGranulo-Hem_ErythroMeg|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung

SLC14A1 SLC18A2 SLC4A1

8.44e-05175223c33317d8d60ea88ec326daf91dfd3416a62f9938
ToppCelldroplet-Marrow-nan-24m-Lymphocytic-immature_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC14A1 ITSN1 SLC4A1

8.58e-05176223fc51e4dcad5456c229d76fdcb9a80c4c79eacf3f
ToppCellTCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma-1|TCGA-Liver / Sample_Type by Project: Shred V9

ARHGEF38 MYOF FAM117B

8.87e-0517822351c59dabf2d7aef1b1964f6f766d5ec07ef90f5a
ToppCellFetal_29-31_weeks-Mesenchymal-pericyte_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

MYOF UXS1 RYR2

9.94e-05185223a7dba7db79275884b2a93d8a16f2e0c739e71370
ToppCell10x5'v1-week_17-19-Hematopoietic-erythroid-mid_erythroid|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 ITSN1 SLC4A1

9.94e-05185223e9059cefcdf0972ec90793b1dd34c3292b17a061
ToppCellPCW_10-12-Hematologic_ErythroMegGranulo-Hem_ErythroMeg|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung

SLC14A1 SLC18A2 SLC4A1

1.01e-041862231c39ced3b32dba2832991284720b6c5f508a2e73
ToppCellFetal_29-31_weeks-Mesenchymal-pericyte_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

MYOF UXS1 RYR2

1.03e-04187223a2bf958ea59c359a265bfa437d59315e1920cdd4
ToppCellMegakaryocytic-erythropoietic-Erythro-cells-Erythrocyte|World / Lineage, cell class and subclass

SLC14A1 ITSN1 SLC4A1

1.06e-04189223826457adac7477102f86aceb97a8b77929b3e6f9
ToppCellMegakaryocytic-erythropoietic-Erythro-cells|World / Lineage, cell class and subclass

SLC14A1 ITSN1 SLC4A1

1.08e-041902236c7e016a9b425ee9418acd4fe96b9779fe7bd39a
ToppCellfacs-Thymus-Flowthrough-3m|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LIPA NDUFA3 SMG7

1.11e-041922237a0ef1702d6538e5611cfdc633d8558f9523845c
ToppCell10x3'2.3-week_12-13-Hematopoietic-erythroid|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 ITSN1 SLC4A1

1.11e-041922236ace9a34ed264583042156ed61c2cb3504a331d2
ToppCellfacs-Thymus-Flowthrough-3m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LIPA NDUFA3 SMG7

1.11e-0419222305043fb75319b64f5ed7aee6a232309dcae891b8
ToppCell10x_3'_v3-bone_marrow_(10x_3'_v3)-hematologic-erythrocytic-erythrocyte|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

SLC14A1 ITSN1 SLC4A1

1.13e-04193223305e15ee467826ee08b2617c69f250ad39c11b19
ToppCell10x_3'_v3-bone_marrow_(10x_3'_v3)-hematologic-erythrocytic|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

SLC14A1 ITSN1 SLC4A1

1.13e-04193223dd376664906caccc9c2065f8e7a364509e18a5cc
ToppCell10x3'2.3-week_12-13-Hematopoietic-erythroid-mid_erythroid|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 ITSN1 SLC4A1

1.13e-041932231e19f80c52833fb21a8d597a3ba2c4ff464c4559
ToppCellMegakaryocytic-erythropoietic-Erythro-cells-Erythrocyte|Megakaryocytic-erythropoietic / Lineage, cell class and subclass

SLC14A1 ITSN1 SLC4A1

1.14e-04194223f0ababe8daa57f6827a3e2e72c884d9e8b2687a3
ToppCell10x3'2.3-week_17-19-Hematopoietic-erythroid-late_erythroid|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 ITSN1 SLC4A1

1.14e-0419422323b06707d21306b4483d64cb350b86aef352ce38
ToppCell10x3'2.3-week_14-16-Hematopoietic-erythroid-mid_erythroid|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 ITSN1 SLC4A1

1.16e-041952234759018a7c016cb2e3df5696f1e5f912c7c9ee17
ToppCell10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_macrophage|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

MYOF LIPA NDUFA3

1.16e-041952234e9513a7ea69fa9fc8e9ff2da8ef3f44e8fdc70d
ToppCell10x3'2.3-week_14-16-Hematopoietic-erythroid|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 ITSN1 SLC4A1

1.16e-04195223b24f6fe71fbcffe7ff1fd1374455c378837d6313
ToppCell10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_macrophage-macrophage|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

MYOF LIPA NDUFA3

1.16e-04195223a25a342380e258b784227f7298f609ccaa1f9ce7
ToppCell10x3'2.3-week_17-19-Hematopoietic-erythroid-mid_erythroid|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 ITSN1 SLC4A1

1.18e-0419622351c48944149a89b98011a50fe81ca6664d5f0d44
ToppCell10x3'2.3-week_17-19-Hematopoietic|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 ITSN1 SLC4A1

1.18e-041962232aeb792e7685e33e3543a6974be790980a41ed8c
ToppCellSkin-Tubules|Skin / Skin and Kidney Cells in Lupus Nephritis Patients.

CFAP47 RYR2 SLC4A1

1.18e-0419622312e21cc310a261407b46e034108e8c93ea16e045
ToppCellMegakaryocytic-erythropoietic-Erythro-cells|Megakaryocytic-erythropoietic / Lineage, cell class and subclass

SLC14A1 ITSN1 SLC4A1

1.18e-04196223092caba6726d1acd409a8be335100764d0724e64
ToppCell10x3'2.3-week_17-19-Hematopoietic-erythroid|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 ITSN1 SLC4A1

1.20e-04197223b71da7f2fd8d526fb6e5d57e60fc08acdd8dbefb
ToppCellControl_saline-Hematopoietic_Erythro-Megakary-Erythro-Mega|Control_saline / Treatment groups by lineage, cell group, cell type

SLC14A1 ITSN1 SLC4A1

1.22e-041982231a39a98beef68e1e6d3adc25270a3336fcc5baf4
ToppCellControl_saline-Hematopoietic_Erythro-Megakary-Erythro-Mega-Erythroid|Control_saline / Treatment groups by lineage, cell group, cell type

SLC14A1 ITSN1 SLC4A1

1.22e-04198223dd80fd9671ee863aebcf4c1023d3e004cc2ee709
ToppCell10x_3'_v3-spleen_(10x_3'_v3)-myeloid-myeloid_macrophage|spleen_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

MYOF LIPA ITSN1

1.22e-041982239aaff68107ae4542f904b142d23669f2fcd557ac
ToppCellControl_saline-Hematopoietic_Erythro-Megakary|Control_saline / Treatment groups by lineage, cell group, cell type

SLC14A1 ITSN1 SLC4A1

1.22e-04198223cfc2a860bae883299987d3e374d0476ca20e1bdd
ToppCell10x3'2.3-week_12-13-Myeloid_macrophage-stroma-stromal_macrophage|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

LIPA NDUFA3 PRDM1

1.22e-041982239a89083280d4253f282300cdf1e61746d1f32407
ToppCell10x_3'_v3-spleen_(10x_3'_v3)-myeloid-myeloid_macrophage-macrophage|spleen_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

MYOF LIPA ITSN1

1.22e-041982235aaf3861c53763cf09bb628c9d2eabb6a7277021
ToppCell10x5'v1-week_14-16-Hematopoietic-erythroid-mid_erythroid|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 ITSN1 SLC4A1

1.23e-04199223e6853b2c0ef6549d5554754c5d5f65825b66025b
ToppCellLPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

MYOF ITSN1 RYR2

1.23e-041992238b86c69aaf60feff53aa782559cfece7342a23de
ToppCell10x5'-lymph-node_spleen-Myeloid_Mac|lymph-node_spleen / Manually curated celltypes from each tissue

MYOF LIPA ITSN1

1.23e-04199223c051cc3e42cfa2ec09fd8dae1172af350bb2dfcb
ToppCell10x3'2.3-week_12-13-Myeloid_macrophage-stroma|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

LIPA NDUFA3 PRDM1

1.23e-0419922352095bff9861aeb5ba0e17ac571ba99d0e5fa940
ToppCell10x5'-lymph-node_spleen-Myeloid_Mac-Erythrophagocytic_macrophages|lymph-node_spleen / Manually curated celltypes from each tissue

MYOF LIPA ITSN1

1.23e-0419922378db2e3b85356ed2f08794e5a97c16a220f8a076
ToppCell10x3'2.3-week_12-13-Myeloid_macrophage|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

LIPA NDUFA3 PRDM1

1.23e-04199223ac2029a023ccad5820d52f19ff9a46feae007c7b
ToppCellLPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

MYOF ITSN1 RYR2

1.25e-042002238988f113708eef7d9d2a6a6c1bcfd7c8f9804d3e
ToppCellLPS_IL1RA-Hematopoietic_Erythro-Megakary-Erythro-Mega-Erythroid|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

SLC14A1 ITSN1 SLC4A1

1.25e-04200223fa1eaf008b54bdf7bbcdec8134460c5f64490de9
ToppCellLPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_only / Treatment groups by lineage, cell group, cell type

MYOF ITSN1 RYR2

1.25e-04200223a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2
ToppCellCOVID-19-COVID-19_Severe-Others-RBC|COVID-19_Severe / Disease, condition lineage and cell class

SLC14A1 ITSN1 SLC4A1

1.25e-04200223308f74e7e13ecc6d133c219c42cc8895a96644c8
ToppCellLPS_IL1RA-Hematopoietic_Erythro-Megakary-Erythro-Mega|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

SLC14A1 ITSN1 SLC4A1

1.25e-04200223f99e214eb680fd82a33f2b1524fbfca265d1cc42
ToppCellLPS_IL1RA-Hematopoietic_Erythro-Megakary|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

SLC14A1 ITSN1 SLC4A1

1.25e-04200223d85074b362b11e5a523a5325d203a61aa2759a7a
ToppCellMonocytes-Donor_04|World / lung cells shred on cell class, cell subclass, sample id

PRDM1 NEB

7.95e-0485222e73603d6f22bb56159aa5d1a2695775f038e61d8
ToppCellDendritic_Cells-Donor_04|World / lung cells shred on cell class, cell subclass, sample id

SLC4A1 NEB

7.95e-0485222d2776a2c8d1721dbbd7d5dc868a3810e30dd9064
ToppCellTracheal-10x5prime-Hematologic-Erythrocyte-Erythrocyte|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

SLC14A1 SLC4A1

1.01e-0396222c3ac1626a3f3931784605f95db1fcdec2c8ad62e
ToppCellTracheal-10x5prime-Hematologic|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

SLC14A1 SLC4A1

1.01e-03962225bd480030df9a4cb8c3b4b6ceee20981fbd67baf
ToppCellTracheal-10x5prime-Hematologic-Erythrocyte|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

SLC14A1 SLC4A1

1.01e-039622274521ab61413f17a9858d3ea4ea63999459aafbc
ToppCelldroplet-Fat-Mat-18m-Hematologic|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC18A2 SLC4A1

1.10e-03100222ea36e4ff513d66186b92e39c549e55c26609cb30
ToppCelldroplet-Fat-Mat-18m-Hematologic-erythroblast|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC18A2 SLC4A1

1.10e-03100222ceca7d9342e5ee7293f07edb815beee4eb010fe7
ToppCellLPS_only-Myeloid-Dendritic_cells-Monocytes-Macrophages|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

LIPA PRDM1

1.37e-031122229801227fe5a6f5ae1b6c5a9e7fa7f35c4c52efe1
ToppCellfrontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Hpse_Cbln4|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

LIPA PRDM1

1.45e-03115222ac73aa06e617ed791c6ae9e38189bac74188c27b
ToppCellCOVID-19_Mild-Hematopoietic_R|COVID-19_Mild / Disease group, lineage and cell class

SLC14A1 SLC4A1

1.57e-0312022235f06e5758f404e94d650e69242e5f44f28816b4
ToppCellCOVID-19_Mild-Hematopoietic_R-RBC|COVID-19_Mild / Disease group, lineage and cell class

SLC14A1 SLC4A1

1.57e-03120222fd500a0034516a83d374d5df03338be6154a4f96
ToppCellmild_COVID-19-RBC|mild_COVID-19 / disease group, cell group and cell class (v2)

SLC14A1 SLC4A1

1.57e-03120222cccea760901558ec18d5cbb71c7971c5a51da571
ToppCellfrontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Hpse_Sema3c|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

LIPA PRDM1

1.63e-03122222eae9d94f8510ac0f434942451d55c7260977b178
ToppCellPBMC-Mild-Hematopoietic-RBC-RBC|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

SLC14A1 SLC4A1

1.65e-03123222cc26155c55e400a0219c5f7f8217aa9c3c912e4e
ToppCellPBMC-Mild-Hematopoietic-RBC|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

SLC14A1 SLC4A1

1.65e-031232227cccdc84130452fa48de47603ab1cc785a0a8c1a
ToppCellPBMC-Mild-Hematopoietic-RBC-RBC-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

SLC14A1 SLC4A1

1.65e-031232229649daf3af2ba6fda4b14925ed03e469496b7a7b
ToppCellPBMC-Mild-Hematopoietic-RBC-RBC-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

SLC14A1 SLC4A1

1.65e-03123222253e401bc546574e0c4a443b3082fb53b4d5ef60
ToppCellPBMC-Mild-Hematopoietic-RBC-RBC|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

SLC14A1 SLC4A1

1.65e-031232228ad6bca3053d1d001f8c34a58374f14c224bf2e7
ToppCellPBMC-Mild-Hematopoietic-RBC|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

SLC14A1 SLC4A1

1.65e-031232224960a126a878791c6bd190d030a9fecd164e9a24
ToppCellprimary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Hpse_Cbln4|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

LIPA PRDM1

1.73e-0312622294bd9cfe982b41a3114885173eab55feb0fbbbae
ToppCellLPS-antiTNF-Myeloid-Dendritic_cells-Monocytes-Macrophages|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

LIPA PRDM1

1.79e-03128222cfc73cb803ba50a4a8709e19e70e1e399118c849
ToppCellwk_08-11-Hematologic-Meg-ery-Definitive_erythrocyte|wk_08-11 / Celltypes from embryonic and fetal-stage human lung

SLC14A1 SLC4A1

1.87e-03131222537a79ea2b5d6b3dc0444570b1acbceda59b0d7c
ToppCell390C-Lymphocytic-NK_cells-NK_cell_B0|390C / Donor, Lineage, Cell class and subclass (all cells)

SLC4A1 PRDM1

1.90e-03132222a1f98d9245c8fe02ea3f098f04919a7d5fc6cbc7
ToppCellLPS-antiTNF-Hematopoietic_Meg-Ery-Mes-Epi-like|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

RYR2 POLR2F

2.01e-03136222a2063abe2d7c3277bfbe1514c8c66363cf04b248
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-Mast-Mast-D|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SLC14A1 SLC4A1

2.01e-0313622294eb78a4b8da307c07c2c4f05b8a14424f887579
ToppCell356C-Lymphocytic-NK_cells-NK_cell_B0|356C / Donor, Lineage, Cell class and subclass (all cells)

SLC14A1 SLC4A1

2.04e-03137222fec21e7a25241289b18aea6a46dc2b981438ebe6
ToppCellE16.5-samps-Mesenchymal-Matrix_fibroblast-_fetal-Intermediate_Fibroblast|E16.5-samps / Age Group, Lineage, Cell class and subclass

GCM2 NEB

2.04e-03137222dd5364a1002650d21e0c83d8c701b5f7b09d1c19
ToppCell356C-Lymphocytic-NK_cells-NK_cell_B0|NK_cells / Donor, Lineage, Cell class and subclass (all cells)

ITSN1 SLC4A1

2.07e-031382222709fb83dfe6c2e27050b08b678a6d6b25d47906
ToppCellLPS_only-Myeloid-Monocytes,_Macrophages-Erythroid|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SLC14A1 SLC4A1

2.10e-03139222d96e5c17582f1576fa09d6bad35c418b6248448c
ToppCell367C-Myeloid-Macrophage-SPP1+_Macrophage_2|367C / Donor, Lineage, Cell class and subclass (all cells)

EIF2AK3 SLC4A1

2.16e-03141222e409da87da5a38ba4d0ccc5e3f8bd89f480f9dab
ToppCellP03-Hematopoietic|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

SLC14A1 SLC4A1

2.16e-031412224a856521520ea73291f4730fe94c5de88c2b6f0c
ToppCelltumor_Lung-T/NK_cells-Naive_CD8+_T|T/NK_cells / Location, Cell class and cell subclass

ARHGEF38 ZNF585A

2.16e-03141222f62d78b3f998f3ea493647c4c5b86cfec2243f0b
ToppCellPBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c05-FOS|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)

SLC4A1 POLR2F

2.19e-03142222ae495c8dd733f0fde66bddc281606543f21c0d4b
ToppCellTCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Malignant_Peripheral_Nerve_Sheath_Tumors|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9

UXS1 POLR2F

2.22e-03143222d1c8e15a8ae2094de2919e99188f9211b78c5abf
ToppCell10x5'v1-week_12-13-Hematopoietic-erythroid-late_erythroid|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

SLC14A1 SLC4A1

2.25e-03144222ca365380ccf5e60d2e3f6272059ff0531759612d
ToppCellP03-Hematopoietic-Erythroid|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

SLC14A1 SLC4A1

2.25e-031442222ee6a834860eac7ed004f366ab4fc38c4b80c905
ToppCellP03-Hematopoietic-Erythroid-enucleate_erythrocyte|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

SLC14A1 SLC4A1

2.25e-031442229fa63904389f4d7163db22ea85ab721d8f6e8d99
ToppCellLPS-IL1RA-Myeloid-Monocytes,_Macrophages-Erythroid|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SLC14A1 SLC4A1

2.25e-031442227c471e332f87d60f4dbed01f3e66bf39995218d0
ToppCellCOVID-19_Severe-MAIT|World / disease group, cell group and cell class

ZNF585A PRDM1

2.28e-031452228d63f97812f63329ef9c940b291dc5a1c4d90690
ToppCell368C-Lymphocytic-NK_cells-NK_cell_A|368C / Donor, Lineage, Cell class and subclass (all cells)

SLC14A1 SLC4A1

2.32e-031462220e38e1fa40b1fcd1bb61f7af7cc2206846c192ae
ToppCellLPS-IL1RA-Myeloid-Dendritic_cells-Monocytes-Macrophages|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

LIPA PRDM1

2.41e-03149222a464c0fd54e3c9e1d40d95b49489cb9371dd7c24
ToppCellCOVID-19_Severe-MAIT|COVID-19_Severe / disease group, cell group and cell class

ZNF585A PRDM1

2.44e-03150222923ea7ecc0aa05fb0396082cd9c3d1594135f1e0
ToppCellHealthy_donor-RBC|World / disease group, cell group and cell class (v2)

SLC14A1 SLC4A1

2.44e-031502221e1a497ec4b048f7e9cc12dd5dd9aba7fedca9e1
DrugAzumoleno

SLC18A2 RYR2

1.87e-057222CID000056259
Drug4-methylumbelliferyl elaidate

LIPA SLC4A1

2.49e-058222CID000087585
DrugPiribedil hydrochloride [78213-63-5]; Up 200; 12uM; PC3; HT_HG-U133A

ARHGEF38 RYR2 SLC4A1 PRDM1

3.73e-052002246333_UP
Drug1,1-dimethylurea

SLC14A1 SLC4A1

5.85e-0512222CID000011737
DrugCocaine

SLC14A1 SLC18A2 EIF2AK3 UXS1 RYR2 POLR2F NEB

1.66e-041314227ctd:D003042
Drugustekinumab

SLC14A1 SLC4A1

2.03e-0422222CID000121749
DrugNeriolin

EIF2AK3 LIPA

2.23e-0423222CID000010057
Drugdiimine

SLC14A1 SLC4A1

2.23e-0423222CID000123195
Drugthiourea

SLC14A1 SLC4A1 GCM2

2.47e-04128223CID002723790
Drugthiophenol

SLC14A1 SLC4A1

2.64e-0425222CID000007969
Drugdodecyl ether

LIPA SLC4A1

2.86e-0426222CID000020667
DrugAC1L18U1

SLC14A1 LIPA

3.81e-0430222CID000000257
Drugtriglyme

SLC14A1 SLC4A1

4.34e-0432222CID000008189
DrugH2DIDS

NDUFA3 SLC4A1

4.62e-0433222CID000115184
Drugl-Lobeline

SLC18A2 SLC4A1

4.91e-0434222CID000003945
DrugVancocine

SLC14A1 SLC4A1

5.82e-0437222CID000005651
Drug8-aminoguanosine

NDUFA3 SLC4A1

6.13e-0438222CID000096849
Drug1ndw

SLC14A1 SLC4A1

6.46e-0439222CID000447340
Drug1d3q

LIPA SLC4A1

6.80e-0440222CID000001635
Drugdipyrone

RYR2 SLC4A1

6.80e-0440222CID000003110
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A

ARHGEF38 EIF2AK3 MYOF

7.03e-041832236944_UP
DrugF0447-0125; Down 200; 10uM; PC3; HT_HG-U133A

SLC14A1 UTP20 MYOF

7.14e-041842236429_DN
DrugDantrolene

EIF2AK3 RYR2

7.14e-0441222ctd:D003620
DrugNiflumic Acid

EIF2AK3 SLC4A1

7.50e-0442222ctd:D009544
DrugR-D-E

SLC18A2 SLC4A1

7.86e-0443222CID011840979
DrugChelidonine monohydrate (+) [476-32-4]; Up 200; 10.8uM; MCF7; HT_HG-U133A

MYOF ITSN1 NEB

7.96e-041912236236_UP
DrugMethylprednisolone, 6-alpha [83-43-2]; Up 200; 10.6uM; MCF7; HT_HG-U133A

SLC18A2 RYR2 NEB

8.20e-041932233183_UP
Druggeldanamycin; Down 200; 1uM; MCF7; HG-U133A

ECE2 SLC4A1 SMG7

8.20e-04193223593_DN
DrugFluticasone propionate [80474-14-2]; Down 200; 8uM; MCF7; HT_HG-U133A

RYR2 SMG7 NEB

8.20e-041932234129_DN
DrugRetrorsine [480-54-6]; Down 200; 11.4uM; HL60; HT_HG-U133A

MYOF ITSN1 NEB

8.20e-041932232129_DN
DrugParbendazole [14255-87-9]; Up 200; 16.2uM; PC3; HT_HG-U133A

ECE2 SMG7 PRDM1

8.32e-041942233799_UP
DrugGabexate mesilate [56974-61-9]; Down 200; 9.6uM; MCF7; HT_HG-U133A

MYOF RYR2 NEB

8.32e-041942234804_DN
DrugPiperacillin sodium salt [59703-84-3]; Down 200; 7.4uM; PC3; HT_HG-U133A

ARHGEF38 SMG7 NEB

8.32e-041942234320_DN
DrugSulfaguanidine [57-67-0]; Down 200; 18.6uM; MCF7; HT_HG-U133A

MYOF RYR2 NEB

8.32e-041942234839_DN
DrugBetahistine mesylate [54856-23-4]; Down 200; 17.2uM; HL60; HT_HG-U133A

MYOF RYR2 NEB

8.32e-041942232472_DN
Drug2-propylpentanoic acid; Down 200; 500uM; HL60; HT_HG-U133A

UTP20 RYR2 PRDM1

8.32e-041942236199_DN
Drug(R)-Propranolol hydrochloride [13071-11-9]; Up 200; 13.6uM; MCF7; HT_HG-U133A

SLC18A2 MYOF NEB

8.45e-041952233553_UP
DrugAmethopterin (R,S) [59-05-2]; Down 200; 8.8uM; PC3; HT_HG-U133A

RYR2 SMG7 NEB

8.45e-041952236654_DN
DrugPrazosin hydrochloride [19237-84-4]; Down 200; 9.6uM; MCF7; HT_HG-U133A

RYR2 SMG7 NEB

8.45e-041952235416_DN
Drugestradiol, USP; Up 200; 0.01uM; MCF7; HT_HG-U133A

MYOF SMG7 NEB

8.58e-041962231666_UP
DrugPramoxine hydrochloride [637-58-1]; Down 200; 12.2uM; HL60; HT_HG-U133A

MYOF ITSN1 RYR2

8.58e-041962232198_DN
DrugCefadroxil [50370-12-2]; Up 200; 11uM; MCF7; HT_HG-U133A

MYOF ITSN1 RYR2

8.58e-041962233259_UP
DrugPizotifen malate [5189-11-7]; Down 200; 9.4uM; PC3; HT_HG-U133A

SLC14A1 SLC18A2 MYOF

8.58e-041962235072_DN
DrugAC1O4QV6

SLC14A1 SLC18A2

8.60e-0445222CID006399008
DrugApramycin [37321-09-8]; Up 200; 7.4uM; PC3; HT_HG-U133A

SLC18A2 ECE2 NEB

8.70e-041972236614_UP
Drug3-alpha-Hydroxy-5-beta-androstan-17-one [53-42-9]; Down 200; 13.8uM; MCF7; HT_HG-U133A

MYOF RYR2 NEB

8.70e-041972233639_DN
Drug(+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Down 200; 11uM; PC3; HT_HG-U133A

SLC14A1 RYR2 NEB

8.70e-041972236663_DN
DrugMidecamycin [35457-80-8]; Down 200; 5uM; MCF7; HT_HG-U133A

MYOF SMG7 NEB

8.70e-041972231526_DN
Drug5155877; Down 200; 10uM; MCF7; HT_HG-U133A

MYOF RYR2 NEB

8.70e-041972236549_DN
DrugChlortetracycline hydrochloride [64-72-2]; Down 200; 7.8uM; MCF7; HT_HG-U133A

MYOF RYR2 SMG7

8.70e-041972231541_DN
DrugNicardipine hydrochloride [54527-84-3]; Up 200; 7.8uM; MCF7; HT_HG-U133A

SLC14A1 ECE2 NEB

8.83e-041982233215_UP
DrugPropantheline bromide [50-34-0]; Down 200; 9uM; MCF7; HT_HG-U133A

MYOF ITSN1 SMG7

8.83e-041982234798_DN
DrugFurosemide [54-31-9]; Up 200; 12uM; MCF7; HT_HG-U133A

MYOF RYR2 PRDM1

8.83e-041982233197_UP
DrugEthotoin [86-35-1]; Up 200; 19.6uM; PC3; HT_HG-U133A

SLC14A1 SMG7 NEB

8.83e-041982233809_UP
DrugFlutamide [13311-84-7]; Up 200; 14.4uM; PC3; HT_HG-U133A

SLC4A1 SMG7 PRDM1

8.83e-041982233803_UP
DrugPipemidic acid [51940-44-4]; Up 200; 13.2uM; HL60; HT_HG-U133A

SLC14A1 RYR2 SMG7

8.83e-041982233093_UP
Drug0225151-0000 [351320-15-5]; Down 200; 10uM; PC3; HT_HG-U133A

ITSN1 SMG7 NEB

8.83e-041982236426_DN
DrugProxyphylline [603-00-9]; Down 200; 16.8uM; HL60; HT_HG-U133A

SMG7 PRDM1 NEB

8.96e-041992233115_DN
Drugretinoic acid; Up 200; 1uM; PC3; HT_HG-U133A

SLC18A2 RYR2 SMG7

8.96e-041992234435_UP
DrugNimodipine [66085-59-4]; Down 200; 9.6uM; MCF7; HT_HG-U133A

RYR2 SMG7 NEB

8.96e-041992235421_DN
DrugLY 294002; Down 200; 0.1uM; HL60; HT_HG-U133A

ARHGEF38 MYOF ITSN1

8.96e-041992232676_DN
Drugmonastrol; Down 200; 100uM; MCF7; HG-U133A

ITSN1 ECE2 SLC4A1

8.96e-04199223596_DN
DrugTheophylline monohydrate [5967-84-0]; Down 200; 20.2uM; HL60; HT_HG-U133A

MYOF SMG7 NEB

8.96e-041992232986_DN
DrugAspartic acid, N-acetyl (R,S) [997-55-7]; Up 200; 22.8uM; MCF7; HT_HG-U133A

MYOF RYR2 NEB

8.96e-041992233265_UP
DrugThyroxine (L) [51-48-9]; Up 200; 5.2uM; MCF7; HT_HG-U133A

MYOF RYR2 PRDM1

8.96e-041992233249_UP
Drugheptachlor epoxide

SLC18A2 SLC4A1

8.99e-0446222CID000013930
Drug100 fM

SLC18A2 SLC4A1

8.99e-0446222CID000023998
DrugPyrantel tartrate [33401-94-4]; Up 200; 11.2uM; MCF7; HT_HG-U133A

MYOF ITSN1 PRDM1

9.09e-042002235513_UP
Drugalpha-estradiol; Down 200; 0.01uM; HL60; HT_HG-U133A

ARHGEF38 MYOF ITSN1

9.09e-042002232670_DN
DrugCAY10397; Up 200; 10uM; MCF7; HT_HG-U133A

MYOF ITSN1 NEB

9.09e-042002237082_UP
DrugIsotretinoin [4759-48-2]; Down 200; 13.4uM; PC3; HT_HG-U133A

MYOF ITSN1 SMG7

9.09e-042002237315_DN
Diseasesystemic lupus erythematosus (implicated_via_orthology)

RC3H1 PRDM1

4.70e-0443222DOID:9074 (implicated_via_orthology)

Protein segments in the cluster

PeptideGeneStartEntry
PNYMYNPIKTLKTNT

UXS1

166

Q8NBZ7
QPSSPKVYLYIQMQL

EIF2AK3

876

Q9NZJ5
KTYNYNVLMVPKPQG

SLC4A1

551

P02730
YSSFLKPYNPAKMQK

ARHGEF38

636

Q9NXL2
QQPPQHSKYKTYMCR

RC3H1

406

Q5TC82
MTPQTVNAYYLPTKN

ECE2

601

P0DPD6
LPKYATSPKPNNSYM

FAM117B

451

Q6P1L5
SPKSNLQYKMYKTPI

ITSN1

1506

Q15811
IYSDSSKVQPLMKPY

RYR2

2746

Q92736
VYKMQFYSSTSPPQK

CFAP47

1566

Q6ZTR5
SKSLQNYIMPYAMTP

UTP20

1606

O75691
TTKVSYQAYQPPAMK

GCM2

386

O75603
GKIMPVKQPYYLQTQ

SMG7

811

Q92540
MTGYKTLPYPLKKQN

PRDM1

556

O75626
QANQKRITTPYMTKY

POLR2F

46

P61218
NSNIYKMPLSKVTYP

SLC14A1

356

Q13336
LSYKQVSSQPQKMYP

ZNF585A

111

Q6P3V2
VSSQPQKMYPGEKAY

ZNF585A

116

Q6P3V2
SPYFKYSVMINKATP

NDUFA3

36

O95167
KTKMYTQNNIQSYPI

SLC18A2

491

Q05940
NQSYPPTYNVKDMLV

LIPA

321

P38571
YSLPNYLSMKIVKPN

MYOF

2046

Q9NZM1
TPKYNPKDSQLYKVM

NEB

5806

P20929